Review article: Cytokines and cancer anorexia cachexia syndrome

American Journal of Hospice and Palliative Medicine

Volumn 25, Issue 5, 2008, Pages 407-411

  Bennani Baiti, Nabila ^a   Davis, Mellar P ^a,b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Anorexia; Cancer; Cancer related cachexia; Cytokines; Tissue wasting

Indexed keywords

CYTOKINE; GHRELIN; INTERLEUKIN 1; INTERLEUKIN 6; LEPTIN; PROTEOGLYCAN; PROTEOLYSIS INDUCING PEPTIDE; PROTEOLYSIS-INDUCING PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANOREXIA; CACHEXIA; HUMAN; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SKELETAL MUSCLE;

ADIPOSE TISSUE; ANOREXIA; CACHEXIA; CYTOKINES; GHRELIN; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; LEPTIN; MUSCLE, SKELETAL; NEOPLASMS; PROTEOGLYCANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 54349085646     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/1049909108315518     Document Type: Review

References (45)

1. Dewys WD, Begg C., Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980 ; 69: 491-497.
2. O'Gorman P., McMillan DC, McArdle CS Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients. Nutr Cancer. 1998 ; 32: 76-80.
3. O'Gorman P., McMillan DC, McArdle CS Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer. 2000 ; 37: 36-40.
4. Tisdale MJ Tumor-host interactions. J Cell Biochem. 2004 ; 93: 871-877.
5. Walsh D., Donnelly S., Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer. 2000 ; 8: 175-179.
6. Yavuzsen T., Davis MP, Walsh D., LeGrand S., Lagman R. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol. 2005 ; 23: 8500-8511.
7. Perboni S., Mantvovani G., Inui A., Takimoto Y. Anorexia: central and peripheral mechanisms. In: Hofbauer KG, Anker S, Inui A, Nicholson JR, eds. Pharmacotherapy of Cachexia. Boca Raton, FL: CRC Press; 2005: 17-30.
8. Laviano A., Meguid MM, Yang ZJ, Gleason JR, Cangiano C., Rossi-Fanelli F. Cracking the riddle of cancer anorexia. Nutrition. 1996 ; 12: 706-710.
9. Martignoni ME, Kunze P., Friess H. Cancer cachexia. Mol Cancer. 2003 ; 2: 36.
10. Laviano A., Meguid MM, Rossi-Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol. 2003 ; 4: 686-694.
11. Shintani F., Kanba S., Nakaki T., et al. Interleukin-1 beta augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus. J Neurosci. 1993 ; 13: 3574-3581.
12. Cangiano C., Cascino A., Ceci F., et al. Plasma and CSF tryptophan in cancer anorexia. J Neural Transm Gen Sect. 1990 ; 81: 225-233.
13. Diksic M., Young SN Study of the brain serotonergic system with labeled alpha-methyl-L-tryptophan. J Neurochem. 2001 ; 78: 1185-1200.
14. Molotkov A., Satoh M., Tohyama C. Tumor growth and food intake in interleukin-6 gene knock-out mice. Cancer Lett. 1998 ; 132: 187-192.
15. Plata-Salaman CR Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition. 2000 ; 16: 1009-1012.
16. Wolf I., Sadetzki S., Kanety H., et al. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer. 2006 ; 106: 966-973.
17. Machado AP, Costa Rosa LF, Seelaender MC Adipose tissue in Walker 256 tumour-induced cachexia: possible association between decreased leptin concentration and mononuclear cell infiltration. Cell Tissue Res. 2004 ; 318: 503-514.
18. Hanada T., Toshinai K., Kajimura N., et al. Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochem Biophys Res Commun. 2003 ; 301: 275-279.
19. Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004 ; 89: 2832-2836.
20. Tisdale MJ Cachexia in cancer patients. Nat Rev Cancer. 2002 ; 2: 862-871.
21. Lecker SH, Solomon V., Mitch WE, Goldberg AL Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr. 1999 ; 129 (1S Suppl.): 227S - 237S.
22. Bossola M., Muscaritoli M., Costelli P., et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol Regul Integr Comp Physiol. 2001 ; 280: R1518 - R1523.
23. Williams A., Sun X., Fischer JE, Hasselgren PO The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery. 1999 ; 126: 744-749 ; discussion 749-750.
24. Baracos VE, DeVivo C., Hoyle DH, Goldberg AL Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am J Physiol. 1995 ; 268 (5 Pt 1). E996 - E1006.
25. Costelli P., Garcia-Martinez C., Llovera M., et al. Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. J Clin Invest. 1995 ; 95: 2367-2372.
26. Broussard SR, McCusker RH, Novakofski JE, et al. Cytokine-hormone interactions: tumor necrosis factor alpha impairs biologic activity and downstream activation signals of the insulin-like growth factor I receptor in myoblasts. Endocrinology. 2003 ; 144: 2988-2996.
27. Frost RA, Lang CH Alteration of somatotropic function by proinflammatory cytokines. J Anim Sci. 2004 ; 82 (E -Suppl.). E100 - E109.
28. Schulze PC, Gielen S., Adams V., et al. Muscular levels of proinflammatory cytokines correlate with a reduced expression of insulinlike growth factor-I in chronic heart failure. Basic Res Cardiol. 2003 ; 98: 267-274.
29. Baracos VE Cytokines and the pathophysiology of skeletal muscle atrophy. In: Hofbauer KG, Anker S, Inui A, Nicholson JR, eds. Pharmacotherapy of Cachexia. Boca Raton, FL: CRC Press; 2005: 101-109.
30. Wigmore SJ, Todorov PT, Barber MD, Ross JA, Tisdale MJ, Fearon KC Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br J Surg. 2000 ; 87: 53-58.
31. Lorite MJ, Smith HJ, Arnold JA, Morris A., Thompson MG, Tisdale MJ Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Br J Cancer. 2001 ; 85: 297-302.
32. Watchorn TM, Waddell I., Dowidar N., Ross JA Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-(kappa)B and STAT3. FASEB J. 2001 ; 15 (3). 562-564.
33. Nelson KA, Walsh D., Sheehan FA The cancer anorexia-cachexia syndrome. J Clin Oncol. 1994 ; 12: 213-225.
34. Legaspi A., Jeevanandam M., Starnes HF Jr, Brennan MF Whole body lipid and energy metabolism in the cancer patient. Metabolism. 1987 ; 36: 958-963.
35. Hirai K., Hussey HJ, Barber MD, Price SA, Tisdale MJ Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res. 1998 ; 58: 2359-2365.
36. Berg M., Fraker DL, Alexander HR Characterization of differentiation factor/leukaemia inhibitory factor effect on lipoprotein lipase activity and mRNA in 3T3-L1 adipocytes. Cytokine. 1994 ; 6: 425-432.
37. Marshall MK, Doerrler W., Feingold KR, Grunfeld C. Leukemia inhibitory factor induces changes in lipid metabolism in cultured adipocytes. Endocrinology. 1994 ; 135: 141-147.
38. Costelli P., Carbo N., Tessitore L., et al. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest. 1993 ; 92: 2783-2789.
39. Klausner JD, Makonkawkeyoon S., Akarasewi P., et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 ; 11: 247-257.
40. Reyes-Terán G., Sierra-Madero JG, Martinez del Cerro V., et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS. 1996 ; 10: 1501-1507.
41. Bruera E., Neumann CM, Pituskin E., Calder K., Ball G., Hanson J. Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Ann Oncol. 1999 ; 10: 857-859.
42. Strassmann G., Fong M., Freter CE, Windsor S., D'Alessandro F., Nordan RP Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J Clin Invest. 1993 ; 92: 2152-2159.
43. Argiles JM, Busquets S., Lopez-Soriano FJ Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care. 2003 ; 6: 401-406.
44. Mori K., Fujimoto-Ouchi K., Ishikawa T., Sekiguchi F., Ishitsuka H., Tanaka Y. Murine interleukin-12 prevents the development of cancer cachexia in a murine model. Int J Cancer. 1996 ; 67: 849-855.
45. Carbo N., Lopez-Soriano J., Costelli P., et al. Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. Br J Cancer. 2000 ; 83: 526-531.